Eli Lilly CEO Reports Strong Adoption of GLP-1 Medications Among New Senior Patients
Eli Lilly CEO Dave Ricks reported to CNBC that approximately 700,000 new seniors have started using GLP-1 treatments since Medicare coverage for obesity drugs began in July. Of these patients, 70% are currently on Eli Lilly medications. This data highlights the expanding access to GLP-1 therapies and suggests that Eli Lilly is gaining a significant share of this growing market compared to its main competitor, Novo Nordisk. Ricks noted that Zepbound has been particularly successful among new patients, especially those with higher body weight and more complications. Additionally, he mentioned the recent launch of Foundayo, an obesity pill from Lilly, which is being used by some seniors seeking a convenient treatment option for modest weight loss goals. Ricks praised Medicare's rollout process as smooth and well-managed. The CEO also indicated that logistical challenges have been minimal so far in implementing coverage under Medicare, with CMS effectively educating physicians and coordinating with pharmaceutical companies.
